US EditionIambic and Revolution Medicines Partner on AI Cancer Drug Discovery
Revolution Medicines, a late-stage clinical oncology company, and Iambic Therapeutics, an AI-driven drug discovery company, have announced a multi-year technology and research collaboration to pursue novel drug candidates using Iambic’s AI models. Iambic will use Revolution Medicine’s structures and molecular libraries to train a bespoke version of NeuralPLexer, Iambic’s AI model for protein-ligand structure prediction. Both companies will ha…
2 Articles
2 Articles
All
Left
Center
Right
Iambic and Revolution Medicines Partner on AI Cancer Drug Discovery
Revolution Medicines, a late-stage clinical oncology company, and Iambic Therapeutics, an AI-driven drug discovery company, have announced a multi-year technology and research collaboration to pursue novel drug candidates using Iambic’s AI models. Iambic will use Revolution Medicine’s structures and molecular libraries to train a bespoke version of NeuralPLexer, Iambic’s AI model for protein-ligand structure prediction. Both companies will ha…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
